News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Smith & Nephew Endoscopy (SNN) Expands Line of CLEAR-TRAC(TM) Surgical Cannulas


12/7/2007 10:05:37 AM

ANDOVER, Mass., Dec. 6 /PRNewswire-FirstCall/ -- Smith & Nephew's Endoscopy Division today announced the launch of a redesigned and expanded family of CLEAR-TRAC Disposable Cannulas, with a new, triple-seal system that reduces fluid leakage and helps surgeons manage sutures during arthroscopic surgery.

Cannulas provide a sterile pathway through which surgeons insert instruments during minimally invasive procedures.

"We have expanded the CLEAR-TRAC cannula family with the introduction of a CLEAR-TRAC Flexible device," said Jonathan Romeo, market manager in Smith & Nephew's Capital business unit. "It features a flexible plastic shaft that provides surgeons with a better feel for changes in tissue density as it is inserted into the body, a feature that surgeons said they sought in a cannula."

The redesigned CLEAR-TRAC COMPLETE and the new CLEAR-TRAC Flexible devices feature a new, patent pending triple-seal system with an integrated suture management system -- specially placed notches in which a surgeon can temporarily segregate and coordinate sutures outside the arthroscopic cavity during procedures.

The new seal system is specifically designed to minimize the leaking and spraying of surgical fluid from the cannula during procedures. Surgeons use sterile solution to distend the joint and create space to maneuver instruments during the repair process. The fluid within the joint is pressurized, to reduce bleeding and to flush away loose bodies or other materials.

"Surgeons who perform arthroscopic procedures expect to get wet, especially later in the surgery, because surgical fluid escapes through the seals when we pass instruments or sutures," said Dr. Marc J. Milia, an orthopedic shoulder specialist with Michigan Orthopedic Specialists in Dearborn, Mich. "The seals on the CLEAR-TRAC cannula minimize leakage of fluid for the duration of the procedure."

In addition to keeping the surgeon and staff dry during a procedure, the new seal system also has the added benefit of reducing procedural costs. "The loss of surgical fluid through the cannulas can add to the cost of each procedure," Dr. Milia added. "The new seals help to reduce these costs by significantly decreasing fluid consumption."

Our expanded cannula line illustrates Smith & Nephew's commitment to listening to and responding to the needs of our surgeon customers and their staffs, Romeo said.

(TM) Trademark of Smith & Nephew. Certain Marks Reg. U.S. Pat. & T.M. Off.

About Us

Smith & Nephew is a global medical technology business, specializing in Orthopaedic Reconstruction, Orthopaedic Trauma and Clinical Therapies, Endoscopy and Advanced Wound Management products. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.

Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company operates in 32 countries around the world. Annual sales in 2006 were nearly $2.8 billion.

Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. In particular, statements regarding planned growth in our business and in our operating margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward- looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.

All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

joe.metzger@smith-nephew.com

CONTACT: Joe Metzger, Vice President, Corporate Communications of Smith &
Nephew Endoscopy, +1-978-749-1330, joe.metzger@smith-nephew.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES